Updates are available Correction dated 2019-07-27

Article History

Received: 18 January 2019

Accepted: 18 April 2019

First Online: 16 May 2019

Change Date: 27 July 2019

Change Type: Correction

Change Details: In the original publication of the article, the Figures 2 and 3 were published incorrectly. The corrected figures are given below,

Compliance with ethical standards

:

: H Hagino reports personal fees from Chugai Pharmaceutical Co., Ltd., during the conduct of the study; grants and other from Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corp., MSD K.K., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Taisho Toyama Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Co., Ltd. and Daiichi Sankyo Co., Ltd.; and other from Eli Lilly Japan K.K., outside the submitted work. A. Sakai received research grants from Astellas Pharma Inc., Asahi Kasei Pharma Corp., Eisai Co., Ltd., Daiichi Sankyo Co., Ltd., Teijin Pharma Ltd., Chugai Pharmaceutical Co., Ltd., and MSD K.K., and lecture fees from Asahi Kasei Corp., Chugai Pharmaceutical Co., Ltd., and Taisho Toyama Pharmaceutical Co., Ltd., outside the submitted work. Y. Imanishi reports grants from Chugai Pharmaceutical Co., Ltd., during the conduct of the study; personal fees from Chugai Pharmaceutical Co., Ltd., outside the submitted work. H. Tsurukami reports personal fees from Chugai Pharmaceutical Co., Ltd., during the conduct of the study, and personal fees from Eli Lilly Japan K.K., outside the submitted work. S. Ikeda, S. Nakajo, and N. Miyakoshi have nothing to disclose.